News

People with pulmonary arterial hypertension (PAH) with at least one coexisting condition associated with cardiovascular disease had similar rates of hospitalization and mortality as those without these conditions after a combination treatment of macitentan and tadalafil, according to a real-world analysis. There was, however, a tendency towards more adverse…

Following the first commercial sale of Yutrepia (treprostinil) inhalation powder to treat certain types of pulmonary hypertension, the therapy’s maker, Liquidia, has received an additional $50 million under its financing agreement with Healthcare Royalty (HCRx). Per that HCR Agreement, Liquidia has been raising funds by selling HCRx…

A Phase 3 clinical trial testing the experimental daily oral treatment ralinepag in people with pulmonary arterial hypertension (PAH) has completed enrollment. The ADVANCE OUTCOMES trial (NCT03626688) enrolled 728 people with PAH who were on oral background therapies. Participants are being randomly assigned to receive ralinepag at doses…

Adding Winrevair (sotatercept-csrk) to background treatment significantly reduces the risk of clinical worsening in people with a recent pulmonary arterial hypertension (PAH) diagnosis, according to results from a Phase 3 clinical trial. The therapy led to “a statistically significant and clinically meaningful reduction in the risk of clinical…

Enrollment is now complete — with nearly 400 participants with pulmonary arterial hypertension (PAH) — in the Phase 3 PROSERA clinical trial that’s testing the PAH treatment candidate seralutinib against a placebo in adults. Top-line results from PROSERA are expected in February 2026, according to Gossamer Bio, which is…

The U.S. Food and Drug Administration (FDA) has accepted Gradient Denervation Technologies, a company that makes an ultrasound-based catheter to treat pulmonary hypertension (PH), into a program to facilitate development of medical devices. Acceptance into the FDA’s Total Product Life Cycle Advisory Program (TAP) pilot will give…

Beyond Air has submitted a supplement application to the U.S. Food and Drug Administration (FDA) for its LungFit PH 2, a second-generation device for administering nitric oxide (NO) to treat persistent pulmonary hypertension of the newborn (PPHN). LungFit PH 2 is a smaller, lightweight, transport-ready version of the…

A Phase 2b clinical trial of Insmed’s treprostinil palmitil inhalation powder (TPIP) suggested daily doses of the inhaled dry powder are well tolerated and may improve blood flow and exercise capacity in adults with pulmonary arterial hypertension (PAH). “The statistically significant and clinically meaningful results shown with TPIP…

The first participant has been dosed in a Phase 1 trial testing F230, an investigational oral therapy for pulmonary arterial hypertension (PAH). This clinical study (NCT06899815) seeks to enroll about 116 healthy individuals in China, ages 18 to 45. Around 68 participants will be randomly assigned to receive a…

A Phase 2a study of HB-1614, an oral therapy candidate, suggested the medication is safe and may improve exercise capacity and quality of life in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD). This is according to Halo Biosciences, developer of HB-1614, which announced the publication of…

Adding more lines of treatment may reduce the risk of rehospitalization among adults with pulmonary arterial hypertension (PAH) who are taking only one medication, a study reports. “Our results suggest that a shift away from monotherapy towards a greater reliance on combination therapy might help to reduce the risk…

People with pulmonary arterial hypertension (PAH) have abnormalities in their gut microbes that may play a role in their disease, a study reports. Transplanting gut microbes from healthy rats into the digestive tract of a rat model of PAH led to a reduction in disease severity, suggesting that targeting…